{"schema_version":"secwatch.filing_event.v1","accession":"0000899923-25-000010","form_type":"8-K","ticker":"MYGN","cik":"0000899923","company_name":"MYRIAD GENETICS INC","filed_at":"2025-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.742813+00:00","generated_at":"2026-05-26T06:40:04.703107+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Myriad Genetics: CEO succession plan; Q4 revenue $211M (+7%), FY 2024 revenue $838M (+11%)","bullets":["CEO Paul J. Diaz resigns effective April 30, 2025; COO Samraat S. Raha appointed President, CEO, and Board member.","Mark S. Verratti promoted to COO effective April 30, succeeding Raha.","Q4 2024 revenue $211M (+7% YoY); full-year revenue $838M (+11% YoY). GAAP net loss $43M (Q4) and $127M (FY).","Adjusted EBITDA Q4 $11M, FY $40M; 2025 guidance reaffirmed: revenue $840-$860M, adjusted EPS $0.07-$0.11.","Exclusive license of PATHOMIQ AI platform for prostate cancer; commercial launch planned later in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000899923-25-000010","json":"https://secwatch.observer/filing/0000899923-25-000010.json","markdown":"https://secwatch.observer/filing/0000899923-25-000010.md","text":"https://secwatch.observer/filing/0000899923-25-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899923/000089992325000010/0000899923-25-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899923/000089992325000010/mygn-20250224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T06:40:04.703107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"19ea312c65","claim":"Samraat S. Raha was appointed as President and Chief Executive Officer at MYRIAD GENETICS INC.","evidence_excerpt":"the Board appointed Samraat S. Raha, the Company's Chief Operating Officer, to succeed Mr. Diaz as its President and Chief Executive Officer on the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/899923/000089992325000010/0000899923-25-000010-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}]},{"claim_id":"a0ce3b4fef","claim":"Samraat S. Raha was appointed as Director at MYRIAD GENETICS INC.","evidence_excerpt":"the Board also appointed Mr. Raha to the Board to serve as a Class II director with a term expiring at the Company’s 2025 Annual Meeting of Stockholders as of the Effective Date to fill the vacancy on the Board that will be created by Mr. Diaz’ resignation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/899923/000089992325000010/0000899923-25-000010-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}]},{"claim_id":"c053a03736","claim":"Paul J. Diaz departed as President and Chief Executive Officer at MYRIAD GENETICS INC.","evidence_excerpt":"Paul J. Diaz, the Company’s President and Chief Executive Officer, announced on February 24, 2025 that he will step down from those positions, and resign from the Company’s Board of Directors (the “Board”), on April 30, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/899923/000089992325000010/0000899923-25-000010-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"President and Chief Executive Officer"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}